By Professor Michael Leonard Friedlander

Journal articles

Sandhu S; Hill A; Gan H; Friedlander M; Voskoboynik M; Barlow P; Townsend A; Song J; Zhang Y; Liang L; Desai J, 2018, 'Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study', Annals of Oncology, 29, pp. x28 - x28, http://dx.doi.org/10.1093/annonc/mdy487.007

Kovalenko S; Crooks R; Provan P; de Fazio A; Taylor P; Kennedy B; Friedlander M; Caramins M, 2018, 'Tumour profiling for treatment of patients with ovarian cancers', Pathology, 50, pp. S77 - S77, http://dx.doi.org/10.1016/j.pathol.2017.12.200

Park SB; Kwok JB; Asher R; Lee CK; Beale P; Selle F; Friedlander M, 2017, 'Clinical and genetic predictors of paclitaxel neurotoxicity based on patient- versus clinicianreported incidence and severity of neurotoxicity in the ICON7 trial', Annals of Oncology, 28, pp. 2733 - 2740, http://dx.doi.org/10.1093/annonc/mdx491

Bookman MA; Okamoto A; Stuart G; Yanaihara N; Aoki D; Bacon M; Fujiwara K; González-Martín A; Harter P; Kim JW; Ledermann J; Pujade-Lauraine E; Quinn M; Ochiai K; Zeimet A; Marth C; du Bois A; Hilpert F; Pfisterer J; Reuss A; Friedlander M; Wilson MK; Kridelka F; Vergote I; Berek J; Dorigo O; Karam A; Bekkers RLM; Westermann A; Gatsonis C; Ng C; Herráez AC; Ottevanger N; Poveda A; Redondo A; Coleman R; Lu K; Gallardo-Rincón D; Gomez-Garcia E; Joly F; Leary A; Ray-Coquard I; Burger R; Moore KN; Fujiwara H; Hasegawa K; Gleeson N; Levy T; Rosengarten O; Katsumata N; Silverberg SG; Sugiyama T; Chang SJ; Kim BG; Nam BH; Colombo N; Ferrero A; Lorusso D; Scambia G; Edmondson R; McNeish I; Kohn E; Hirte H; McGee J; Provencher D; Sehouli J; Wimberger P; Maenpaa J; Mirza MR; Oza A; Welch S; Gaffney D; Small W; Glasspool R; Gourley C; Millan D; Zang R; Zhu J, 2017, 'Harmonising clinical trials within the Gynecologic Cancer InterGroup: Consensus and unmet needs from the Fifth Ovarian Cancer Consensus Conference', Annals of Oncology, 28, pp. viii30 - viii35, http://dx.doi.org/10.1093/annonc/mdx449

Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA; Buck M; Dean A; Friedlander ML; Harnett P; Kichenadasse G; Denys H; Dirix L; Vergote I; Elit L; Ghatage P; Plante M; Provencher D; Welch S; Gladieff L; Joly F; Lortholary A; Lotz J; Medioni J; Tredan O; You B; El-Balat A; Hänle C; Krabisch P; Neunhöffer T; Pölcher M; Wimberger P; Amit A; Kovel S; Leviov M; Safra T; Shapira-Frommer R; Stemmer S; Bologna A; Pignata S; Sabbatini RF; Tamberi S; Zamagni C; O'Donnell A; Herraez AC; Guerra EM; Palacio I; Romero I; Sanchez A; Banerjee SN; Drew Y; Gabra HG; Jackson D; Parkinson C; Powell M; Birrer MJ; Buss MK; Chambers SK; Chen LM; Ma L; Morgan MA; Morris RT; Mutch DG; Slomovitz BM; Vanderkwaak T; Vulfovich M, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial', The Lancet, 390, pp. 1949 - 1961, http://dx.doi.org/10.1016/S0140-6736(17)32440-6

Coleman RL; Oza AM; Lorusso D, 2017, 'Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial (vol 390, pg 1949, 2017)', LANCET, 390, pp. 1948 - 1948, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000413823200030&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lee YC; Bressel M; Grant P; Russell P; Smith C; Picken S; Camm S; Kiely BE; Milne RL; McLachlan SA; Hickey M; Friedlander ML; Hopper JL; Phillips KA, 2017, 'Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer', Familial Cancer, 16, pp. 461 - 469, http://dx.doi.org/10.1007/s10689-017-9977-x

Lee YC; Milne RL; Lheureux S; Friedlander M; McLachlan SA; Martin KL; Bernardini MQ; Smith C; Picken S; Nesci S; Hopper JL; Phillips KA, 2017, 'Risk of uterine cancer for BRCA1 and BRCA2 mutation carriers', European Journal of Cancer, 84, pp. 114 - 120, http://dx.doi.org/10.1016/j.ejca.2017.07.004

Pujade-Lauraine E; Ledermann JA; Selle F; Gebski V; Penson RT; Oza AM; Korach J; Huzarski T; Poveda A; Pignata S; Friedlander M; Colombo N; Harter P; Fujiwara K; Ray-Coquard IL; Banerjee S; Liu J; Lowe ES; Bloomfield R; Pautier P; Byrski T; Colombo N; Scambia G; Nicoletto M; Nussey F; Clamp A; Poveda Velasco A; Rodrigues M; Lotz JP; Provencher D; Prat Aparicio A; Vidal Boixader L; Scott C; Tamura K; Yunokawa M; Lisyanskaya A; Medioni J; Pécuchet N; Dubot C; de la Motte Rouge T; Kaminsky MC; Weber B; Lortholary A; Parkinson C; Williams S; Cosin J; Hoffman J; Plante M; Covens A; Sonke G; Joly F; Floquet A; Hirte H; Amit A; Park-Simon TW; Matsumoto K; Tjulandin S; Kim JH; Gladieff L; Sabbatini R; O'Malley D; Timmins P; Kredentser D; Laínez Milagro N; Barretina Ginesta MP; Tibau Martorell A; Gómez de Liaño Lista A; Ojeda González B; Mileshkin L; Mandai M; Boere I; Ottevanger P; Nam JH; Filho E; Hamizi S; Cognetti F; Warshal D; Dickson-Michelson E; Kamelle S; McKenzie N; Rodriguez G; Armstrong D; Chalas E; Celano P; Behbakht K; Davidson S; Welch S; Helpman L; Fishman A; Bruchim I, 2017, 'Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial', The Lancet Oncology, 18, pp. 1274 - 1284, http://dx.doi.org/10.1016/S1470-2045(17)30469-2

Roncolato FT; Joly F; O’Connell R; Lanceley A; Hilpert F; Buizen L; Okamoto A; Aotani E; Pignata S; Donnellan P; Oza A; Avall-Lundqvist E; Berek JS; Heitz F; Feeney A; Berton-Rigaud D; Stockler MR; King M; Friedlander M, 2017, 'Reducing uncertainty: Predictors of stopping chemotherapy early and shortened survival time in platinum resistant/refractory ovarian cancer—The GCIG symptombenefit study', Oncologist, 22, pp. 1117 - 1124, http://dx.doi.org/10.1634/theoncologist.2017-0047

Gligorov J; Ataseven B; Verrill M; de Laurentiis M; Jung KH; Azim HA; Al-Sakaff N; Lauer S; Shing M; Pivot X; Koroveshi D; Bouzid K; Casalnuovo M; Cascallar D; Korbenfeld EP; Bastick P; Beith J; Colosimo M; Friedlander M; Ganju V; Green M; Patterson K; Redfern A; Richardson G; Ceric T; Gordana K; Beato CA; Ferrari M; Hegg R; Helena V; Ismael GF; Lessa AE; Mano M; Morelle A; Nogueira JA; Timcheva K; Tomova A; Tsakova M; Zlatareva-Petrova A; Asselah J; Assi H; Brezden-Masley C; Chia S; Freedman O; Harb M; Joy AA; Kulkarni S; Prady C; Gaete AAA; Matamala L; Torres R; Yanez E; Franco S; Urrego M; Gugić D; Vrbanec D; Melichar B; Prausová J; Vyzula R; Pilarte RG; León MI; Muñoz R; Ramos G; Azeem HA; Aziz AA; El Zawahry H; Osegueda FR; Alexandre J; Artignan X; Barletta H; Beguier E; Berdah JF; Marty CB; Bollet M; Bourgeois H; Bressac C; Burki F; Campone M; Coeffic D; Cojocarasu OZ; Dagada C; Dalenc F; Del Piano F; Desauw C; Desmoulins I; Dohollou N; Egreteau J; Ferrero JM; Foa C; Garidi R; Gasnault L; Guardiola E; Hamizi S; Jarcau R; Jacquin JP; Jaubert D; Jolimoy G; Mineur HL; Largillier R; Leduc B, 2017, 'Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients', European Journal of Cancer, 82, pp. 237 - 246, http://dx.doi.org/10.1016/j.ejca.2017.05.010

Kondrashova O; Nguyen M; Shield-Artin K; Tinker AV; Teng NNH; Harrell MI; Kuiper MJ; Ho GY; Barker H; Jasin M; Prakash R; Kass EM; Sullivan MR; Brunette GJ; Bernstein KA; Coleman RL; Floquet A; Friedlander M; Kichenadasse G; O’Malley DM; Oza A; Sun J; Robillard L; Maloney L; Bowtell D; Giordano H; Wakefield MJ; Kaufmann SH; Simmons AD; Harding TC; Raponi M; McNeish IA; Swisher EM; Lin KK; Scott CL, 2017, 'Secondary somatic mutations restoring RAD51C and RAD51D associated with acquired resistance to the PARP inhibitor rucaparib in high-grade ovarian carcinoma', Cancer Discovery, 7, pp. 984 - 998, http://dx.doi.org/10.1158/2159-8290.CD-17-0419

Mercieca-Bebber R; Friedlander M; Kok PS; Calvert M; Kyte D; Stockler M; King MT, 2017, 'Erratum to: The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols (Quality of Life Research, (2016), 25, 10, (2457-2465), 10.1007/s11136-016-1339-x)', Quality of Life Research, 26, pp. 2249 - 2250, http://dx.doi.org/10.1007/s11136-017-1578-5

Roncolato FT; Gibbs E; Lee CK; Asher R; Davies LC; Gebski VJ; Friedlander M; Hilpert F; Wenzel L; Stockler MR; King M; Pujade-Lauraine E, 2017, 'Quality of life predicts overall survival in women with platinum-resistant ovarian cancer: An AURELIA substudy', Annals of Oncology, 28, pp. 1849 - 1855, http://dx.doi.org/10.1093/annonc/mdx229

Samimi G; Caga-Anan CF; Dean M; Mechanic LE; Minasian LM; Sherman ME; Brody LC; Bernardini MQ; Lheureux S; Shaw PA; Kwon JS; Campbell IG; James PA; Takenaka M; Bowtell DD; Chenevix-Trench G; Friedlander M; Ramus SJ; Couch FJ; De Hullu JA; Harmsen MG; Domchek SM; Drapkin R; Mai PL; Feigelson HS; Gaudet MM; Hurley K; Robson ME; Lacbawan F; Slavin TP; Myers ER; Rezende LF; Swisher EM, 2017, 'Traceback: A proposed framework to increase identification and genetic counseling of BRCA1 and BRCA2 mutation carriers through family-based outreach', Journal of Clinical Oncology, 35, pp. 2329 - 2337, http://dx.doi.org/10.1200/JCO.2016.70.3439

Kuchenbaecker KB; Hopper JL; Barnes DR; Phillips KA; Mooij TM; Roos-Blom MJ; Jervis S; van Leeuwen FE; Milne RL; Andrieu N; Goldgar DE; Terry MB; Rookus MA; Easton DF; Antoniou AC; McGuffog L; Evans DG; Barrowdale D; Frost D; Adlard J; Ong KR; Izatt L; Tischkowitz M; Eeles R; Davidson R; Hodgson S; Ellis S; Nogues C; Lasset C; Stoppa-Lyonnet D; Fricker JP; Faivre L; Berthet P; Hooning MJ; van der Kolk LE; Kets CM; Adank MA; John EM; Chung WK; Andrulis IL; Southey M; Daly MB; Buys SS; Osorio A; Engel C; Kast K; Schmutzler RK; Caldes T; Jakubowska A; Simard J; Friedlander ML; McLachlan SA; Machackova E; Foretova L; Tan YY; Singer CF; Olah E; Gerdes AM; Arver B; Olsson H, 2017, 'Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers', JAMA, 317, pp. 2402 - 2416, http://dx.doi.org/10.1001/jama.2017.7112

Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L, 2017, 'Factors Associated with Deciding between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical and Gynecological Survey, 72, pp. 336 - 337, http://dx.doi.org/10.1097/OGX.0000000000000451

Bonaventura A; O'Connell RL; Mapagu C; Beale PJ; McNally OM; Mileshkin LR; Grant PT; Hadley AM; Goh JCH; Sjoquist KM; Martyn J; DeFazio A; Scurry J; Friedlander ML, 2017, 'Paragon (ANZGOG-0903): Phase 2 study of anastrozole in women with estrogen or progesterone receptorypositive platinum-resistant or -refractory recurrent ovarian cancer', International Journal of Gynecological Cancer, 27, pp. 900 - 906, http://dx.doi.org/10.1097/IGC.0000000000000978

Gourley C; Friedlander M; Matulonis UA; Shirinkin V; Selle F; Scott CL; Safra T; Fielding A; Rowe P; Ledermann JA, 2017, 'Clinically significant long-term maintenance treatment with olaparib in patients (pts) with platinum-sensitive relapsed serous ovarian cancer (PSR SOC).', Journal of Clinical Oncology, 35, pp. 5533 - 5533, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.5533

Lee CK; Scott CL; Lindeman GJ; Gibbs E; Badger HD; Paterson RJ; Macnab L; Kwan EM; Boyle FM; Friedlander M, 2017, 'Phase I study of olaparib (O), in combination with oral cyclophosphamide (C), in patients (pts) with metastatic triple negative breast cancer (TNBC) and recurrent high grade serous ovarian cancer (OVCA).', Journal of Clinical Oncology, 35, pp. 1104 - 1104, http://dx.doi.org/10.1200/jco.2017.35.15_suppl.1104

Webber K; Friedlander M, 2017, 'Chemotherapy for epithelial ovarian, fallopian tube and primary peritoneal cancer', Best Practice and Research: Clinical Obstetrics and Gynaecology, 41, pp. 126 - 138, http://dx.doi.org/10.1016/j.bpobgyn.2016.11.004

Rodgers RJ; Reid GD; Koch J; Deans R; Ledger WL; Friedlander M; Gilchrist RB; Walters KA; Abbott JA, 2017, 'The safety and efficacy of controlled ovarian hyperstimulation for fertility preservation in women with early breast cancer: A systematic review', Human Reproduction, 32, pp. 1033 - 1045, http://dx.doi.org/10.1093/humrep/dex027

Sousa MS; Peate M; Jarvis S; Hickey M; Friedlander M, 2017, 'A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy', Therapeutic Advances in Medical Oncology, 9, pp. 269 - 285, http://dx.doi.org/10.1177/1758834016687260

Wilson MK; Pujade-Lauraine E; Aoki D; Mirza MR; Lorusso D; Oza AM; du Bois A; Vergote I; Reuss A; Bacon M; Friedlander M; Gallardo-Rincon D; Joly F; Chang SJ; Ferrero AM; Edmondson RJ; Wimberger P; Maenpaa J; Gaffney D; Zang R; Okamoto A; Stuart G; Ochiai K, 2017, 'Fifth ovarian cancer consensus conference of the gynecologic cancer intergroup: Recurrent disease', Annals of Oncology, 28, pp. 727 - 732, http://dx.doi.org/10.1093/annonc/mdw663

Sandler CX; Goldstein D; Horsfield S; Bennett BK; Friedlander M; Bastick PA; Lewis CR; segelov E; Boyle FM; Chin MT; webber K; Barry BK; Lloyd AR, 2017, 'Randomized evaluation of cognitive-behavioral therapy and graded exercise therapy for post-cancer fatigue.', Journal of Pain and Symptom Management, http://dx.doi.org/10.1016/j.jpainsymman.2017.03.015

Rungruang BJ; Miller A; Krivak TC; Horowitz NS; Rodriguez N; Hamilton CA; Backes FJ; Carson LF; Friedlander M; Mutch DG; Goodheart MJ; Tewari KS; Wenham RM; Bookman MA; Maxwell GL; Richard SD, 2017, 'What is the role of retroperitoneal exploration in optimally debulked stage IIIC epithelial ovarian cancer? An NRG Oncology/Gynecologic Oncology Group ancillary data study', Cancer, 123, pp. 985 - 993, http://dx.doi.org/10.1002/cncr.30414

Isakoff SJ; Puhalla S; Domchek SM; Friedlander M; Kaufman B; Robson M; Telli ML; Diéras V; Han HS; Garber JE; Johnson EF; Maag D; Qin Q; Giranda VL; Shepherd SP, 2017, 'A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: Design and rationale', Future Oncology, 13, pp. 307 - 320, http://dx.doi.org/10.2217/fon-2016-0412

Mercieca-Bebber R; Friedlander M; Calvert M; Stockler M; Kyte D; Kok PS; King MT, 2017, 'A systematic evaluation of compliance and reporting of patient-reported outcome endpoints in ovarian cancer randomised controlled trials: Implications for generalisability and clinical practice', Journal of Patient-Reported Outcomes, 1, http://dx.doi.org/10.1186/s41687-017-0008-3

Rafii S; Gourley C; Kumar R; Geuna E; Ang JE; Rye T; Chen LM; Shapira-Frommer R; Friedlander M; Matulonis U; De Greve J; Oza AM; Banerjee S; Rhoda Molife L; Gore ME; Kaye SB; Yap TA, 2017, 'Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer', Oncotarget, 8, pp. 47154 - 47160, http://dx.doi.org/10.18632/oncotarget.17005

Pickett JL; Chou A; Andrici JA; Clarkson A; Sioson L; Sheen A; Reagh J; Najdawi F; Kim Y; Riley D; Maidens J; Nevell D; McIlroy K; Valmadre S; Gard G; Hogg R; Turchini J; Robertson G; Friedlander M; Gill AJ, 2017, 'Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required', American Journal of Surgical Pathology, 41, pp. 1433 - 1442, http://dx.doi.org/10.1097/PAS.0000000000000909

Wilson MK; Friedlander ML; Lheureux S; Small W; Poveda A; Pujade-Lauraine E; Karakasis K; Bacon M; Bowering V; Chawla T; Oza AM, 2017, 'Resisting RECISTV uniformity versus clinical validity', International Journal of Gynecological Cancer, 27, pp. 1619 - 1627, http://dx.doi.org/10.1097/IGC.0000000000001062

Hettle R; Sackeyfio A; Gill J; Siddiqui K; Nussey F; Friedlander M, 2017, 'Comparative Efficacy And Safety Of Olaparib 300 Mg Tablets Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients With Platinum-Sensitive Relapsed Germline BRCA-Mutated Ovarian Cancer (PSROC)', Value in Health, 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.088

Sackeyfio A; Gill J; Hettle R; Siddiqui K; Friedlander M; Ledermann JA, 2017, 'Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC)', Value in Health, 20, pp. A412 - A412, http://dx.doi.org/10.1016/j.jval.2017.08.087

Penson R; Kaminsky-Forrett M-C; Ledermann J; Brown C; Plante M; Korach J; Huzarski T; Gomez de Liano Lista A; Pisano C; Friedlander M; Colombo N; Gropp-Meier M; Nakai H; Sonke GS; Kim J-W; Vergote I; Allen A; Pujade-Lauraine E, 2017, 'Efficacy of olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSROC) by lines of prior chemotherapy: Phase III SOLO2 trial (ENGOT Ov-21)', Annals of Oncology, 28, pp. v331 - v331, http://dx.doi.org/10.1093/annonc/mdx372.002

Mai PL; Piedmonte M; Han PK; Moser RP; Walker JL; Rodriguez G; Boggess J; Rutherford TJ; Zivanovic O; Cohn DE; Thigpen JT; Wenham RM; Friedlander ML; Hamilton CA; Bakkum-Gamez J; Olawaiye AB; Hensley ML; Greene MH; Huang HQ; Wenzel L, 2017, 'Factors Associated With Deciding Between Risk-Reducing Salpingo-oophorectomy and Ovarian Cancer Screening Among High-Risk Women Enrolled in GOG-0199: An NRG Oncology/Gynecologic Oncology Group Study', Obstetrical & Gynecological Survey, 72, pp. 336 - 337, http://dx.doi.org/10.1097/ogx.0000000000000451

Scerri TS; Quaglieri A; Cai C; Zernant J; Matsunami N; Baird L; Scheppke L; Bonelli R; Yannuzzi LA; Friedlander M; MacTel Project Consortium ; Egan CA; Fruttiger M; Leppert M; Allikmets R; Bahlo M, 2017, 'Genome-wide analyses identify common variants associated with macular telangiectasia type 2.', Nat Genet, 49, pp. 559 - 567, http://dx.doi.org/10.1038/ng.3799

Ritchie G; Gasper H; Man J; Lord S; Friedlander M; Lee C; Marschner I, 2017, 'Is objective response rate (ORR) a valid primary endpoint in phase 2 trials (Ph2t) of immune checkpoint inhibitors (ICI) for advanced solid cancers?', Annals of Oncology, 28, pp. v411 - v411, http://dx.doi.org/10.1093/annonc/mdx376.023

Meniawy T; Richardson G; Townsend A; Desai J; Gan H; Friedlander M; Horvath L; Jameson MB; Sandhu S; Wu Z; Qin Z; Kang K; Markman B, 2017, 'Preliminary results from a subset of patients (pts) with advanced ovarian cancer (OC) in a dose-escalation/expansion study of BGB-A317, an anti-PD-1 monoclonal antibody (mAb)', Annals of Oncology, 28, pp. v130 - v130, http://dx.doi.org/10.1093/annonc/mdx367.023

Thewes B; Prins J; Friedlander M, 2016, '70-Gene signature in early-stage breast cancer', New England Journal of Medicine, 375, pp. 2199 - 2200, http://dx.doi.org/10.1056/NEJMc1612048

Lawrence N; Martin A; Toner G; Stockler M; Buizen L; Thomson D; Gebski V; Friedlander M; Yeung A; Wong N; Gurney H; Rosenthal M; Singhal N; Kichenadasse G; Wong S; Lewis C; Vasey P; Grimison P, 2016, 'Long-term outcomes of accelerated BEP (bleomycin, etoposide, cisplatin) for advanced germ cell tumours: updated analysis of an Australian multicentre phase II trial by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP)', Annals of Oncology, 27, pp. 2302 - 2303, http://dx.doi.org/10.1093/annonc/mdw313

Friedlander M; Banerjee S; Mileshkin L; Scott C; Shannon C; Goh J, 2016, 'Practical guidance on the use of olaparib capsules as maintenance therapy for women with BRCA mutations and platinum-sensitive recurrent ovarian cancer', Asia-Pacific Journal of Clinical Oncology, 12, pp. 323 - 331, http://dx.doi.org/10.1111/ajco.12636

Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P, 2016, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumours (vol 46, pg 893, 2016)', INTERNAL MEDICINE JOURNAL, 46, pp. 1459 - 1459, http://dx.doi.org/10.1111/imj.13259

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Bennett B; Parry D; Spencer S; Mann H; Matulonis U, 2016, 'Quality of life during olaparib maintenance therapy in platinum-sensitive relapsed serous ovarian cancer', British Journal of Cancer, 115, pp. 1313 - 1320, http://dx.doi.org/10.1038/bjc.2016.348

Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U, 2016, 'Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial', The Lancet Oncology, 17, pp. 1579 - 1589, http://dx.doi.org/10.1016/S1470-2045(16)30376-X

Pulford DJ; Harter P; Floquet A; Barrett C; Suh DH; Friedlander M; Arranz JA; Hasegawa K; Tada H; Vuylsteke P; Mirza MR; Donadello N; Scambia G; Johnson T; Cox C; Chan JK; Imhof M; Herzog TJ; Calvert P; Wimberger P; Berton-Rigaud D; Lim MC; Elser G; Xu CF; Du Bois A, 2016, 'Communicating BRCA research results to patients enrolled in international clinical trials: Lessons learnt from the AGO-OVAR 16 study', BMC Medical Ethics, 17, pp. 63, http://dx.doi.org/10.1186/s12910-016-0144-y

Mercieca-Bebber R; Friedlander M; Kok PS; Calvert M; Kyte D; Stockler M; King MT, 2016, 'The patient-reported outcome content of international ovarian cancer randomised controlled trial protocols', Quality of Life Research, 25, pp. 2457 - 2465, http://dx.doi.org/10.1007/s11136-016-1339-x

Phillips KA; Collins IM; Milne RL; McLachlan SA; Friedlander M; Hickey M; Stern C; Hopper JL; Fisher R; Kannemeyer G; Picken S; Smith CD; Kelsey TW; Anderson RA, 2016, 'Anti-müllerian hormone serum concentrations of women with germline BRCA1 or BRCA2 mutations', Obstetrical and Gynecological Survey, 71, pp. 474 - 475, http://dx.doi.org/10.1097/01.ogx.0000489566.21546.e2

Lehane C; Ho F; Thompson SR; Links D; Lewis C; Smee R; Parasyn A; Friedlander M; Williams J; Crowe P, 2016, 'Neoadjuvant chemoradiation (modified Eilber protocol) versus adjuvant radiotherapy in the treatment of extremity soft tissue sarcoma', Journal of Medical Imaging and Radiation Oncology, 60, pp. 539 - 544, http://dx.doi.org/10.1111/1754-9485.12442

Ferraro D; Goldstein D; O'Connell RL; Zalcberg JR; Sjoquist KM; Tebbutt NC; Grimison P; McLachlan S; Lipton LL; Vasey P; Gebski VJ; Aiken C; Cronk M; Ng S; Karapetis CS; Shannon J; Do V; Marschner I; Friedlander M; Gurney H; Simes J; Hague W; O’Connell R; Gorzeman M; Pike R; Miranda K; Waring P; Lau D; Fox S; Liu Y; Wood T; Cocks C; Simmons K; McCourt J; Jefford M; Hobinchet A; Mirco B; Sagong J; Dudukovic S; Aghmesheh M; Parker S; Segelov E; Ratnayake L; Ranieri N; Varma S; Page J; Heyer E; Abdi E; Chorlton C; Wilkinson L; Marshall I, 2016, 'TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer', Cancer Chemotherapy and Pharmacology, 78, pp. 361 - 367, http://dx.doi.org/10.1007/s00280-016-3089-4

Roncolato FT; Chatfield M; Houghton B; Toner G; Stockler M; Thomson D; Friedlander M; Gurney H; Rosenthal M; Grimison P, 2016, 'The effect of pulmonary function testing on bleomycin dosing in germ cell tumours', Internal Medicine Journal, 46, pp. 893 - 898, http://dx.doi.org/10.1111/imj.13158

Back to profile page